Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (952) clinical trials

People who may develop Alzheimer's Disease are asked to participate in a research study being conducted by New York University School of Medicine.

Phase N/A

The study will evaluate the efficacy, safety, and tolerability of a medication: AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type. Approximately 325 patients will be enrolled at approximately 50 centers in North America.

Phase

This study tests whether two investigational drugs called CAD106 and CNP520, administered separately, can delay and slow the progression of clinical symptoms associated with Alzheimer's Disease in participants at risk of developing clinical symptoms based on their age and genotype.   Other Details: https://clinicaltrials.gov/ct2/show/NCT02565511

Phase

Evaluate the efficacy of Lanabecestat in mild Alzheimer's Disease dementia   Other Details:  https://clinicaltrials.gov/ct2/show/study/NCT02783573

Phase

People with Schizophrenia are asked to participate in a research study being conducted by Zucker Hillside Hospital.

Phase N/A

The primary objective is to evaluate the effects of administration of neflamapimod (VX-745) for 24-weeks on immediate and delayed recall aspects of episodic memory, as assessed by the Hopkins Verbal Learning Test – Revised (HVLT-R) in subjects with mild Alzheimer’s disease (AD).

Phase

The purpose of this research study is to measure the effects of a study drug on body weight in young adults that have schizophrenia, schizophreniform or bipolar 1 disorder. This study will last approximately 20 weeks. There will be 11 study visits. Each visit lasts between 1 and 4 hours. ...

Phase N/A

This is a randomized placebo-controlled trial in individuals with Parkinson's disease dementia to evaluate the safety and efficacy of three doses of a study drug in participants with mild-to-moderate Parkinson's disease dementia treated for 12 weeks.  

Phase

Eligible participants for this study must have a diagnosis of probable AD and must have clinically meaningful agitation secondary to AD. This is a multicenter, randomized, placebo-controlled study, consisting of 12 weeks of treatment. Approximately 470 participants will be enrolled at approximately 75 centers in North America. Study medication will ...

Phase N/A